-
-
Toggle navigation
The 1st most cited open-access journal in Pharmacology & Pharmacy
Submit your manuscript
Scope
This section is focused on the discovery of molecular targets in cancer, targetable molecules in cancer signaling pathways, and their eventual application in drug development and therapeutics. One of the greatest challenges after the discovery of cancer specific targets is to decipher the complexity of the targetable protein function and to develop innovative target-only drugs which selectively fight cancer but not normal cells. Given the explosion of new information in molecular oncogenesis and the rapidly growing momentum of target-specific therapies, our section highlights new discoveries, approaches, and technical developments in cancer molecular target identification, drug development as well as discovery-driven cancer translational research. With this in mind, we aim to translate the fundamental knowledge of oncogenes and tumor suppressor genes into prototypes for cancer therapy. Priority will be given to preclinical and translational evaluations of novel targets and functioning of the target specific therapeutics. Submissions should present significant new information on the mechanisms of targetable molecules in cancer development and metastasis and target-specific therapies. Drug actions encompassing the following areas: cancer targetable genes, innovative models of target-specific therapies, drug sensitivity and resistance, pharmacokinetics and pharmacodynamics, gene therapy, and early-stage development of promising new target-specific compounds are also welcomed submissions.Indexed in: PubMed, PubMed Central, Scopus, Web of Science, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS)
Cancer Molecular Targets and Therapeutics welcomes submissions of the following article types: Book Review, Case Report, Clinical Trial, Correction, Data Report, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Protocols, Review, Specialty Grand Challenge, Systematic Review and Technology Report.
All manuscripts must be submitted directly to the section Cancer Molecular Targets and Therapeutics, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Cancer Molecular Targets and Therapeutics will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Pharmacology and Oncology.
Frontiers Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
Frontiers Support
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
support@frontiersin.org
There are no results to display.
Click on any of the keywords to find further editors related to it.
- Article(s) found
- Latest
- Most viewed
This section has no articles.
There are no articles to display. Please try changing the filters.
- Research Topic(s) found
- Latest
- Most viewed
Contact Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01